Senate investigations panel to probe Mylan's EpiPen pricing
WASHINGTON, Sept 7 (Reuters) - The U.S. Senate's permanent subcommittee on investigations has decided to look into Mylan Pharmaceuticals' pricing of the EpiPen, according to a press release issued on Wednesday.
The release described the probe as a "preliminary inquiry."
(Reporting by Diane Bartz; Editing by Chris Reese)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.
